SCHEMBL8295451

SCHEMBL8295451

Cc1nc(-c2c(Cl)cccc2Cl)no1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 2/20 0.44
ADORA3 P0DMS8 2/20 0.43
TSHR P16473 1/20 0.42
PDK2 Q15119 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
KDM4E B2RXH2 2/20 0.40
PLK1 P53350 1/20 0.40
NTRK1 P04629 1/20 0.40
PIM1 P11309 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
DGAT1 O75907 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14363623 0.88 L3MBTL1 (0.50) L3MBTL1MAPTALDH1A1LMNAADORA3
SCHEMBL14363610 0.84 L3MBTL1 (0.46) L3MBTL1MAPTALDH1A1LMNAGAA
SCHEMBL16067418 0.82 L3MBTL1 (0.51) L3MBTL1MAPTGAAPDK2KDM4E
SCHEMBL14363630 0.82 L3MBTL1 (0.51) L3MBTL1MAPTGAAPDK2KDM4E
SCHEMBL9987876 0.81 L3MBTL1 (0.50) L3MBTL1MAPTALDH1A1GAATSHR
SCHEMBL9782317 0.76 L3MBTL1 (0.38) L3MBTL1MAPTALDH1A1LMNAGAA
SCHEMBL25426498 0.76 L3MBTL1 (0.53) L3MBTL1MAPTGAATSHRCA12
SCHEMBL15677598 0.76 ACACB (0.44) MAPTTSHRNPSR1DGAT1NPC1
SCHEMBL9782308 0.74 STAT3 (0.40) L3MBTL1MAPTALDH1A1LMNAGAA
SCHEMBL14363634 0.74 L3MBTL1 (0.77) L3MBTL1MAPTLMNATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7947834-B2 Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators SANOFI-AVENTIS (FR) 2011-05-24 US disclosed
US-7947834-B2 Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators SANOFI-AVENTIS (FR) 2011-05-24 US disclosed
US-20090176775-A1 DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
US-20090176775-A1 DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE SANOFI-AVENTIS (FR) 2009-07-09 US disclosed
US-20070259874-A1 Phosphodiesterase Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2007-11-08 US disclosed
US-20070259874-A1 Phosphodiesterase Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2007-11-08 US disclosed
WO-2005051931-A2 PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-06-09 WO disclosed
US-4160829-A ANTIBIOTICS GIST-BROCADES N.V. (NL) 1979-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176775-A1 DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE HSD11B1, HSD3B1, ADH1C L3MBTL1 4567/4885MAPT 1529/4885ALDH1A1 46/4885
US-20070259874-A1 Phosphodiesterase Inhibitors PDE4A, PDE3B, PDE7A L3MBTL1 4801/4885MAPT 2797/4885ALDH1A1 940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.